New treatment option for nasopharyngeal cancer patients

The CUHK-led study on “Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)” demonstrates immunotherapy to be effective in patients with advanced nasopharyngeal cancer. The landmark findings represent a new treatment option for NPC patients and researchers hope to extend the benefits of immunotherapy to other types of cancer in the future (J Clin Oncol. 2018 Mar 27:JCO2017770388. doi:10.1200/JCO.2017.77.0388 [Epub ahead of print]).
 
Anyone interested in future collaboration in this field of research is welcome to contact our key investigator Prof Brigette Ma of our Department of Clinical Oncology. Prof Ma’s interest is in new drug development and clinical research: designing and conducting phase I clinical trials, novel therapies for nasopharyngeal carcinoma, colorectal cancer and other gastrointestinal cancers.
 
Read the full article: http://ascopubs.org/doi/pdf/10.1200/JCO.2017.77.0388